Mayme Loyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mayme Loyd has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey Comer
Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas 66506, United States
3 shared publications - Masaaki Tamura
Department of Anatomy & Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA
3 shared publications - Ayaka Nakashima
Euglena Co., Ltd., Tokyo 108-0014, Japan
2 shared publications - Azhagiya Singam Ettayapuram Ramaprasad
Molecular Graphics and Computation Facility, College of Chemistry, University of California, Berkeley, CA 94720, USA
2 shared publications - Deepa Upreti
Departments of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA
2 shared publications - Kengo Suzuki
Euglena Co., Ltd, 1-6, Suehiro-Cho, Tsurumi-Ku, Yokohama City, Kanagawa, 230-0045, Japan
2 shared publications
Latest Publications
- Open Access
- 3 January 2022
- Published by Elsevier in Translational Oncology
- Vol. 16, 101337
Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice
- 3 January 2022
- Published by Elsevier in Translational Oncology
- Vol. 16, 101337
Open AccessLocal immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice
- Open Access
- 18 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 3124
Beta-1,3 Oligoglucans Specifically Bind to Immune Receptor CD28 and May Enhance T Cell Activation
Beta glucans are known to have immunomodulatory effects that mediated by a variety of mechanisms. In this article, we describe experiments and simulations suggesting that beta-1,3 glucans may promote activation of T cells by a previously unknown mechanism. First, we find that treatment of a T lymphoblast cell line with beta-1,3 oligoglucan significantly increases mRNA levels of T cell activation-associated cytokines, especially in the presence of the agonistic anti-CD3 antibody. This immunostimulatory activity was observed in the absence of dectin-1, a known receptor for beta-1,3 glucans. To clarify the molecular mechanism underlying this activity, we performed a series of molecular dynamics simulations and free-energy calculations to explore the interaction of beta-1,3 oligoglucans with potential immune receptors. While the simulations reveal little association between beta-1,3 oligoglucan and the immune receptor CD3, we find that beta-1,3 oligoglucans bind to CD28 near the region identified as the binding site for its natural ligands CD80 and CD86. Using a rigorous absolute binding free-energy technique, we calculate a dissociation constant in the low millimolar range for binding of 8-mer beta-1,3 oligoglucan to this site on CD28. The simulations show this binding to be specific, as no such association is computed for alpha-1,4 oligoglucan. This study suggests that beta-1,3 glucans bind to CD28 and may stimulate T cell activation collaboratively with T cell receptor activation, thereby stimulating immune function.
- 18 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 3124
Open AccessBeta-1,3 Oligoglucans Specifically Bind to Immune Receptor CD28 and May Enhance T Cell Activation
Beta glucans are known to have immunomodulatory effects that mediated by a variety of mechanisms. In this article, we describe experiments and simulations suggesting that beta-1,3 glucans may promote activation of T cells by a previously unknown mechanism. First, we find that treatment of a T lymphoblast cell line with beta-1,3 oligoglucan significantly increases mRNA levels of T cell activation-associated cytokines, especially in the presence of the agonistic anti-CD3 antibody. This immunostimulatory activity was observed in the absence of dectin-1, a known receptor for beta-1,3 glucans. To clarify the molecular mechanism underlying this activity, we performed a series of molecular dynamics simulations and free-energy calculations to explore the interaction of beta-1,3 oligoglucans with potential immune receptors. While the simulations reveal little association between beta-1,3 oligoglucan and the immune receptor CD3, we find that beta-1,3 oligoglucans bind to CD28 near the region identified as the binding site for its natural ligands CD80 and CD86. Using a rigorous absolute binding free-energy technique, we calculate a dissociation constant in the low millimolar range for binding of 8-mer beta-1,3 oligoglucan to this site on CD28. The simulations show this binding to be specific, as no such association is computed for alpha-1,4 oligoglucan. This study suggests that beta-1,3 glucans bind to CD28 and may stimulate T cell activation collaboratively with T cell receptor activation, thereby stimulating immune function.
- Open Access
- 1 July 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 127, 110166
Water extract from Euglena gracilis prevents lung carcinoma growth in mice by attenuation of the myeloid-derived cell population
- 1 July 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 127, 110166
Open AccessWater extract from Euglena gracilis prevents lung carcinoma growth in mice by attenuation of the myeloid-derived cell population